21ьз╕ C

Genmab Announces that Janssen has Submitted a Biologics License Application to U.S. FDA for Amivantamab in Non-small Cell Lung Cancer

News Provided by GlobeNewswire2020-12-03

Media Release

Copenhagen, Denmark, December 3, 2020

Janssen submitted a BLA to U.S. FDA for amivantamab for patients with non-small cell lung cancer with epidermal growth factor receptor Exon 20 insertion mutations
First regulatory submission for a DuoBody^Â® product candidate

Genmab A/S (Nasdaq: GMAB) announced today that Janssen Biotech, Inc. (Janssen) submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (U.S. FDA) seeking approval of amivantamab for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy.This is the first BLA submission for a product candidate that was created using Genmabâ€™s proprietary DuoBody technology platform. In July 2012, Genmab entered into a collaboration with Janssen to create and develop bispecific antibodies using Genmabâ€™s DuoBody technology platform.

â€œTodayâ€™s milestone underscores the promise of our DuoBody technology platform to effectively create innovative and truly differentiated bispecific antibody therapeutics,â€ said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.

For more information related to Janssenâ€™s amivantamab filing click here.

About Non-small Cell Lung Cancer
Lung cancer is the most common cancer worldwide. Approximately 80 to 85 percent of lung cancers are classified as NSCLC and include subtypes adenocarcinoma, squamous cell carcinoma and large cell carcinoma^1,2. Mutations in the EGFR gene are common in patients with NSCLC, including 10 to 15 percent of NSCLC patients in Western countries.^3,4 The five-year survival rate for all patients with metastatic NSCLC with EGFR mutations who are treated with EGFR tyrosine kinase inhibitors is less than 20 percent.^5,6 In addition, the estimated median overall survival for patients with NSCLC and EGFR Exon 20 insertion mutations is shorted than in patients with common EGFR mutations.⁷

About Genmab
Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company is the creator of the following approved antibodies: DARZALEX^Â® (daratumumab, under agreement with Janssen Biotech, Inc.) for the treatment of certain multiple myeloma indications in territories including the U.S., Europe and Japan, Kesimpta^Â® (subcutaneous ofatumumab, under agreement with Novartis AG), for the treatment of adults with relapsing forms of multiple sclerosis in the U.S. and TEPEZZA^Â®(teprotumumab, under agreement with Roche granting sublicense to Horizon Therapeutics plc) for the treatment of thyroid eye disease in the U.S. A subcutaneous formulation of daratumumab, known as DARZALEX FASPROâ„¢ (daratumumab and hyaluronidase-fihj) in the U.S., has been approved in the U.S. and Europe for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy, Arzerra^Â® (ofatumumab, under agreement with Novartis AG), approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Daratumumab is in clinical development by Janssen for the treatment of additional multiple myeloma indications, other blood cancers and amyloidosis. Genmab also has a broad clinical and pre-clinical product pipeline. Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody^Â® platform for generation of bispecific antibodies, the HexaBody^Â® platform, which creates effector function enhanced antibodies, the HexElect^Â® platform, which combines two co-dependently acting HexaBody molecules to introduce selectivity while maximizing therapeutic potency and the DuoHexaBody^Â® platform, which enhances the potential potency of bispecific antibodies through hexamerization. The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies. Genmab is headquartered in Copenhagen, Denmark with sites in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan.

Contact:Â Â Â Â Â Â Â Â Â Â
Marisol Peron, Corporate Vice President, Communications & Investor Relations
T: +1 609 524 0065; E: mmp@genmab.com

For Investor Relations:
Andrew Carlsen, Senior Director, Investor Relations
T: +45 3377 9558; E: acn@genmab.com

This Media Release contains forward looking statements. The words â€œbelieveâ€, â€œexpectâ€, â€œanticipateâ€, â€œintendâ€ and â€œplanâ€ and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmabâ€™s most recent financial reports, which are available onwww.genmab.com and the risk factors included in Genmabâ€™s most recent Annual Report on Form 20-F and other filingswith the U.S. Securities and Exchange Commission (SEC), which are available atwww.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in this Media Release nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

Genmab A/S and/or its subsidiaries own the following trademarks: Genmab^Â®; the Y-shaped Genmab logo^Â®; Genmab in combination with the Y-shaped Genmab logo^Â®; HuMax^Â®; DuoBody^Â®; DuoBody in combination with the DuoBody logo^Â®; HexaBody^Â®; HexaBody in combination with the HexaBody logo^Â®; DuoHexaBody^Â®; HexElect^Â®; and UniBody^Â®. Arzerra^Â® and Kesimpta^Â®are trademarks of Novartis AG or its affiliates. DARZALEX^Â® and DARZALEX FASPROâ„¢ are trademarks of Janssen Pharmaceutica NV. TEPEZZA^Â® is a trademark of Horizon Therapeutics plc.

¹ The World Health Organization. Cancer.Â https://www.who.int/news-room/fact-sheets/detail/cancer.
² American Cancer Society. What is Lung Cancer? https://www.cancer.org/content/cancer/en/cancer/lung-cancer/about/what-is.html.
³ Van Assche, Katrijn, et al. â€œEGFR Mutation Positive Stage IV Non-Small-Cell Lung Cancer: Treatment Beyond Progression.â€ Frontiers in Oncology, Frontiers Media S.A., 8 Dec. 2014, www.ncbi.nlm.nih.gov/pmc/articles/PMC4259002/.
⁴ Midha, Anita, et al. â€œEGFR Mutation Incidence in Non-Small-Cell Lung Cancer of Adenocarcinoma Histology: a Systematic Review and Global Map by Ethnicity (MutMapII).â€ American Journal of Cancer Research, e-Century Publishing Corporation, 15 Aug. 2015, www.ncbi.nlm.nih.gov/pmc/articles/PMC4633915/.
⁵ Howlader N, Noone AM, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2016, National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2016/, based on November 2018 SEER data submission, posted to the SEER web site
⁶ Lin JJ, Cardarella S, Lydon CA, Dahlberg SE, Jackman DM, JÃ¤nne PA, et al. Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs. J Thorac Oncol. 2016 Apr;11(4):556-65.
⁷Oxnard, JR et. al. Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions. J Thorac Oncol. 2013 Feb;8(2):179-84. doi: 10.1097/JTO.0b013e3182779d18.